[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Biosimilar Monoclonal Antibodies Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

January 2024 | 97 pages | ID: G557F977E23EN
GlobalInfoResearch

US$ 3,480.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
According to our (Global Info Research) latest study, the global Biosimilar Monoclonal Antibodies market size was valued at USD 4639.7 million in 2023 and is forecast to a readjusted size of USD 12580 million by 2030 with a CAGR of 15.3% during review period.

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.

Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.

In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.

The Global Info Research report includes an overview of the development of the Biosimilar Monoclonal Antibodies industry chain, the market status of Oncology (Infliximab, Rituximab), Autoimmune Disease (Infliximab, Rituximab), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Biosimilar Monoclonal Antibodies.

Regionally, the report analyzes the Biosimilar Monoclonal Antibodies markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Biosimilar Monoclonal Antibodies market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Biosimilar Monoclonal Antibodies market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Biosimilar Monoclonal Antibodies industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Infliximab, Rituximab).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Biosimilar Monoclonal Antibodies market.

Regional Analysis: The report involves examining the Biosimilar Monoclonal Antibodies market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Biosimilar Monoclonal Antibodies market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Biosimilar Monoclonal Antibodies:

Company Analysis: Report covers individual Biosimilar Monoclonal Antibodies manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Biosimilar Monoclonal Antibodies This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Oncology, Autoimmune Disease).

Technology Analysis: Report covers specific technologies relevant to Biosimilar Monoclonal Antibodies. It assesses the current state, advancements, and potential future developments in Biosimilar Monoclonal Antibodies areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Biosimilar Monoclonal Antibodies market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Biosimilar Monoclonal Antibodies market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
  • Infliximab
  • Rituximab
  • Trastuzumab
  • Adalimumab
  • Other
Market segment by Application
  • Oncology
  • Autoimmune Disease
  • Other
Major players covered
  • Celltrion
  • Pfizer (Hospira)
  • 3SBIO
  • Novartis (Sandoz)
  • Dr Reddy’s
  • Celgen Biopharma
  • Cadila Healthcare
  • Hisun Pharma
  • Torrent Pharmaceuticals
Market segment by region, regional analysis covers
  • North America (United States, Canada and Mexico)
  • Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
  • Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
  • South America (Brazil, Argentina, Colombia, and Rest of South America)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Biosimilar Monoclonal Antibodies product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Biosimilar Monoclonal Antibodies, with price, sales, revenue and global market share of Biosimilar Monoclonal Antibodies from 2019 to 2024.

Chapter 3, the Biosimilar Monoclonal Antibodies competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Biosimilar Monoclonal Antibodies breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Biosimilar Monoclonal Antibodies market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Biosimilar Monoclonal Antibodies.

Chapter 14 and 15, to describe Biosimilar Monoclonal Antibodies sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW

1.1 Product Overview and Scope of Biosimilar Monoclonal Antibodies
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
  1.3.1 Overview: Global Biosimilar Monoclonal Antibodies Consumption Value by Type: 2019 Versus 2023 Versus 2030
  1.3.2 Infliximab
  1.3.3 Rituximab
  1.3.4 Trastuzumab
  1.3.5 Adalimumab
  1.3.6 Other
1.4 Market Analysis by Application
  1.4.1 Overview: Global Biosimilar Monoclonal Antibodies Consumption Value by Application: 2019 Versus 2023 Versus 2030
  1.4.2 Oncology
  1.4.3 Autoimmune Disease
  1.4.4 Other
1.5 Global Biosimilar Monoclonal Antibodies Market Size & Forecast
  1.5.1 Global Biosimilar Monoclonal Antibodies Consumption Value (2019 & 2023 & 2030)
  1.5.2 Global Biosimilar Monoclonal Antibodies Sales Quantity (2019-2030)
  1.5.3 Global Biosimilar Monoclonal Antibodies Average Price (2019-2030)

2 MANUFACTURERS PROFILES

2.1 Celltrion
  2.1.1 Celltrion Details
  2.1.2 Celltrion Major Business
  2.1.3 Celltrion Biosimilar Monoclonal Antibodies Product and Services
  2.1.4 Celltrion Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  2.1.5 Celltrion Recent Developments/Updates
2.2 Pfizer (Hospira)
  2.2.1 Pfizer (Hospira) Details
  2.2.2 Pfizer (Hospira) Major Business
  2.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product and Services
  2.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  2.2.5 Pfizer (Hospira) Recent Developments/Updates
2.3 3SBIO
  2.3.1 3SBIO Details
  2.3.2 3SBIO Major Business
  2.3.3 3SBIO Biosimilar Monoclonal Antibodies Product and Services
  2.3.4 3SBIO Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  2.3.5 3SBIO Recent Developments/Updates
2.4 Novartis (Sandoz)
  2.4.1 Novartis (Sandoz) Details
  2.4.2 Novartis (Sandoz) Major Business
  2.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product and Services
  2.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  2.4.5 Novartis (Sandoz) Recent Developments/Updates
2.5 Dr Reddy’s
  2.5.1 Dr Reddy’s Details
  2.5.2 Dr Reddy’s Major Business
  2.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Product and Services
  2.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  2.5.5 Dr Reddy’s Recent Developments/Updates
2.6 Celgen Biopharma
  2.6.1 Celgen Biopharma Details
  2.6.2 Celgen Biopharma Major Business
  2.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Product and Services
  2.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  2.6.5 Celgen Biopharma Recent Developments/Updates
2.7 Cadila Healthcare
  2.7.1 Cadila Healthcare Details
  2.7.2 Cadila Healthcare Major Business
  2.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Product and Services
  2.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  2.7.5 Cadila Healthcare Recent Developments/Updates
2.8 Hisun Pharma
  2.8.1 Hisun Pharma Details
  2.8.2 Hisun Pharma Major Business
  2.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Product and Services
  2.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  2.8.5 Hisun Pharma Recent Developments/Updates
2.9 Torrent Pharmaceuticals
  2.9.1 Torrent Pharmaceuticals Details
  2.9.2 Torrent Pharmaceuticals Major Business
  2.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product and Services
  2.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  2.9.5 Torrent Pharmaceuticals Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: BIOSIMILAR MONOCLONAL ANTIBODIES BY MANUFACTURER

3.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Manufacturer (2019-2024)
3.2 Global Biosimilar Monoclonal Antibodies Revenue by Manufacturer (2019-2024)
3.3 Global Biosimilar Monoclonal Antibodies Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
  3.4.1 Producer Shipments of Biosimilar Monoclonal Antibodies by Manufacturer Revenue ($MM) and Market Share (%): 2023
  3.4.2 Top 3 Biosimilar Monoclonal Antibodies Manufacturer Market Share in 2023
  3.4.2 Top 6 Biosimilar Monoclonal Antibodies Manufacturer Market Share in 2023
3.5 Biosimilar Monoclonal Antibodies Market: Overall Company Footprint Analysis
  3.5.1 Biosimilar Monoclonal Antibodies Market: Region Footprint
  3.5.2 Biosimilar Monoclonal Antibodies Market: Company Product Type Footprint
  3.5.3 Biosimilar Monoclonal Antibodies Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global Biosimilar Monoclonal Antibodies Market Size by Region
  4.1.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Region (2019-2030)
  4.1.2 Global Biosimilar Monoclonal Antibodies Consumption Value by Region (2019-2030)
  4.1.3 Global Biosimilar Monoclonal Antibodies Average Price by Region (2019-2030)
4.2 North America Biosimilar Monoclonal Antibodies Consumption Value (2019-2030)
4.3 Europe Biosimilar Monoclonal Antibodies Consumption Value (2019-2030)
4.4 Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value (2019-2030)
4.5 South America Biosimilar Monoclonal Antibodies Consumption Value (2019-2030)
4.6 Middle East and Africa Biosimilar Monoclonal Antibodies Consumption Value (2019-2030)

5 MARKET SEGMENT BY TYPE

5.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
5.2 Global Biosimilar Monoclonal Antibodies Consumption Value by Type (2019-2030)
5.3 Global Biosimilar Monoclonal Antibodies Average Price by Type (2019-2030)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
6.2 Global Biosimilar Monoclonal Antibodies Consumption Value by Application (2019-2030)
6.3 Global Biosimilar Monoclonal Antibodies Average Price by Application (2019-2030)

7 NORTH AMERICA

7.1 North America Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
7.2 North America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
7.3 North America Biosimilar Monoclonal Antibodies Market Size by Country
  7.3.1 North America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2030)
  7.3.2 North America Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2030)
  7.3.3 United States Market Size and Forecast (2019-2030)
  7.3.4 Canada Market Size and Forecast (2019-2030)
  7.3.5 Mexico Market Size and Forecast (2019-2030)

8 EUROPE

8.1 Europe Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
8.2 Europe Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
8.3 Europe Biosimilar Monoclonal Antibodies Market Size by Country
  8.3.1 Europe Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2030)
  8.3.2 Europe Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2030)
  8.3.3 Germany Market Size and Forecast (2019-2030)
  8.3.4 France Market Size and Forecast (2019-2030)
  8.3.5 United Kingdom Market Size and Forecast (2019-2030)
  8.3.6 Russia Market Size and Forecast (2019-2030)
  8.3.7 Italy Market Size and Forecast (2019-2030)

9 ASIA-PACIFIC

9.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Biosimilar Monoclonal Antibodies Market Size by Region
  9.3.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Region (2019-2030)
  9.3.2 Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value by Region (2019-2030)
  9.3.3 China Market Size and Forecast (2019-2030)
  9.3.4 Japan Market Size and Forecast (2019-2030)
  9.3.5 Korea Market Size and Forecast (2019-2030)
  9.3.6 India Market Size and Forecast (2019-2030)
  9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
  9.3.8 Australia Market Size and Forecast (2019-2030)

10 SOUTH AMERICA

10.1 South America Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
10.2 South America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
10.3 South America Biosimilar Monoclonal Antibodies Market Size by Country
  10.3.1 South America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2030)
  10.3.2 South America Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2030)
  10.3.3 Brazil Market Size and Forecast (2019-2030)
  10.3.4 Argentina Market Size and Forecast (2019-2030)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Biosimilar Monoclonal Antibodies Market Size by Country
  11.3.1 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2030)
  11.3.2 Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2030)
  11.3.3 Turkey Market Size and Forecast (2019-2030)
  11.3.4 Egypt Market Size and Forecast (2019-2030)
  11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
  11.3.6 South Africa Market Size and Forecast (2019-2030)

12 MARKET DYNAMICS

12.1 Biosimilar Monoclonal Antibodies Market Drivers
12.2 Biosimilar Monoclonal Antibodies Market Restraints
12.3 Biosimilar Monoclonal Antibodies Trends Analysis
12.4 Porters Five Forces Analysis
  12.4.1 Threat of New Entrants
  12.4.2 Bargaining Power of Suppliers
  12.4.3 Bargaining Power of Buyers
  12.4.4 Threat of Substitutes
  12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of Biosimilar Monoclonal Antibodies and Key Manufacturers
13.2 Manufacturing Costs Percentage of Biosimilar Monoclonal Antibodies
13.3 Biosimilar Monoclonal Antibodies Production Process
13.4 Biosimilar Monoclonal Antibodies Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel
  14.1.1 Direct to End-User
  14.1.2 Distributors
14.2 Biosimilar Monoclonal Antibodies Typical Distributors
14.3 Biosimilar Monoclonal Antibodies Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

LIST OF TABLES

Table 1. Global Biosimilar Monoclonal Antibodies Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Biosimilar Monoclonal Antibodies Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Celltrion Basic Information, Manufacturing Base and Competitors
Table 4. Celltrion Major Business
Table 5. Celltrion Biosimilar Monoclonal Antibodies Product and Services
Table 6. Celltrion Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Celltrion Recent Developments/Updates
Table 8. Pfizer (Hospira) Basic Information, Manufacturing Base and Competitors
Table 9. Pfizer (Hospira) Major Business
Table 10. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product and Services
Table 11. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Pfizer (Hospira) Recent Developments/Updates
Table 13. 3SBIO Basic Information, Manufacturing Base and Competitors
Table 14. 3SBIO Major Business
Table 15. 3SBIO Biosimilar Monoclonal Antibodies Product and Services
Table 16. 3SBIO Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. 3SBIO Recent Developments/Updates
Table 18. Novartis (Sandoz) Basic Information, Manufacturing Base and Competitors
Table 19. Novartis (Sandoz) Major Business
Table 20. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product and Services
Table 21. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Novartis (Sandoz) Recent Developments/Updates
Table 23. Dr Reddy’s Basic Information, Manufacturing Base and Competitors
Table 24. Dr Reddy’s Major Business
Table 25. Dr Reddy’s Biosimilar Monoclonal Antibodies Product and Services
Table 26. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. Dr Reddy’s Recent Developments/Updates
Table 28. Celgen Biopharma Basic Information, Manufacturing Base and Competitors
Table 29. Celgen Biopharma Major Business
Table 30. Celgen Biopharma Biosimilar Monoclonal Antibodies Product and Services
Table 31. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. Celgen Biopharma Recent Developments/Updates
Table 33. Cadila Healthcare Basic Information, Manufacturing Base and Competitors
Table 34. Cadila Healthcare Major Business
Table 35. Cadila Healthcare Biosimilar Monoclonal Antibodies Product and Services
Table 36. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Cadila Healthcare Recent Developments/Updates
Table 38. Hisun Pharma Basic Information, Manufacturing Base and Competitors
Table 39. Hisun Pharma Major Business
Table 40. Hisun Pharma Biosimilar Monoclonal Antibodies Product and Services
Table 41. Hisun Pharma Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Hisun Pharma Recent Developments/Updates
Table 43. Torrent Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 44. Torrent Pharmaceuticals Major Business
Table 45. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product and Services
Table 46. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. Torrent Pharmaceuticals Recent Developments/Updates
Table 48. Global Biosimilar Monoclonal Antibodies Sales Quantity by Manufacturer (2019-2024) & (K Units)
Table 49. Global Biosimilar Monoclonal Antibodies Revenue by Manufacturer (2019-2024) & (USD Million)
Table 50. Global Biosimilar Monoclonal Antibodies Average Price by Manufacturer (2019-2024) & (USD/Unit)
Table 51. Market Position of Manufacturers in Biosimilar Monoclonal Antibodies, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 52. Head Office and Biosimilar Monoclonal Antibodies Production Site of Key Manufacturer
Table 53. Biosimilar Monoclonal Antibodies Market: Company Product Type Footprint
Table 54. Biosimilar Monoclonal Antibodies Market: Company Product Application Footprint
Table 55. Biosimilar Monoclonal Antibodies New Market Entrants and Barriers to Market Entry
Table 56. Biosimilar Monoclonal Antibodies Mergers, Acquisition, Agreements, and Collaborations
Table 57. Global Biosimilar Monoclonal Antibodies Sales Quantity by Region (2019-2024) & (K Units)
Table 58. Global Biosimilar Monoclonal Antibodies Sales Quantity by Region (2025-2030) & (K Units)
Table 59. Global Biosimilar Monoclonal Antibodies Consumption Value by Region (2019-2024) & (USD Million)
Table 60. Global Biosimilar Monoclonal Antibodies Consumption Value by Region (2025-2030) & (USD Million)
Table 61. Global Biosimilar Monoclonal Antibodies Average Price by Region (2019-2024) & (USD/Unit)
Table 62. Global Biosimilar Monoclonal Antibodies Average Price by Region (2025-2030) & (USD/Unit)
Table 63. Global Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2024) & (K Units)
Table 64. Global Biosimilar Monoclonal Antibodies Sales Quantity by Type (2025-2030) & (K Units)
Table 65. Global Biosimilar Monoclonal Antibodies Consumption Value by Type (2019-2024) & (USD Million)
Table 66. Global Biosimilar Monoclonal Antibodies Consumption Value by Type (2025-2030) & (USD Million)
Table 67. Global Biosimilar Monoclonal Antibodies Average Price by Type (2019-2024) & (USD/Unit)
Table 68. Global Biosimilar Monoclonal Antibodies Average Price by Type (2025-2030) & (USD/Unit)
Table 69. Global Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 70. Global Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 71. Global Biosimilar Monoclonal Antibodies Consumption Value by Application (2019-2024) & (USD Million)
Table 72. Global Biosimilar Monoclonal Antibodies Consumption Value by Application (2025-2030) & (USD Million)
Table 73. Global Biosimilar Monoclonal Antibodies Average Price by Application (2019-2024) & (USD/Unit)
Table 74. Global Biosimilar Monoclonal Antibodies Average Price by Application (2025-2030) & (USD/Unit)
Table 75. North America Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2024) & (K Units)
Table 76. North America Biosimilar Monoclonal Antibodies Sales Quantity by Type (2025-2030) & (K Units)
Table 77. North America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 78. North America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 79. North America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2024) & (K Units)
Table 80. North America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2025-2030) & (K Units)
Table 81. North America Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
Table 82. North America Biosimilar Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
Table 83. Europe Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2024) & (K Units)
Table 84. Europe Biosimilar Monoclonal Antibodies Sales Quantity by Type (2025-2030) & (K Units)
Table 85. Europe Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 86. Europe Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 87. Europe Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2024) & (K Units)
Table 88. Europe Biosimilar Monoclonal Antibodies Sales Quantity by Country (2025-2030) & (K Units)
Table 89. Europe Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
Table 90. Europe Biosimilar Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
Table 91. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2024) & (K Units)
Table 92. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Type (2025-2030) & (K Units)
Table 93. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 94. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 95. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Region (2019-2024) & (K Units)
Table 96. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity by Region (2025-2030) & (K Units)
Table 97. Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value by Region (2019-2024) & (USD Million)
Table 98. Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value by Region (2025-2030) & (USD Million)
Table 99. South America Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2024) & (K Units)
Table 100. South America Biosimilar Monoclonal Antibodies Sales Quantity by Type (2025-2030) & (K Units)
Table 101. South America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 102. South America Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 103. South America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2019-2024) & (K Units)
Table 104. South America Biosimilar Monoclonal Antibodies Sales Quantity by Country (2025-2030) & (K Units)
Table 105. South America Biosimilar Monoclonal Antibodies Consumption Value by Country (2019-2024) & (USD Million)
Table 106. South America Biosimilar Monoclonal Antibodies Consumption Value by Country (2025-2030) & (USD Million)
Table 107. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Type (2019-2024) & (K Units)
Table 108. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Type (2025-2030) & (K Units)
Table 109. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Application (2019-2024) & (K Units)
Table 110. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Application (2025-2030) & (K Units)
Table 111. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Region (2019-2024) & (K Units)
Table 112. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity by Region (2025-2030) & (K Units)
Table 113. Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value by Region (2019-2024) & (USD Million)
Table 114. Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value by Region (2025-2030) & (USD Million)
Table 115. Biosimilar Monoclonal Antibodies Raw Material
Table 116. Key Manufacturers of Biosimilar Monoclonal Antibodies Raw Materials
Table 117. Biosimilar Monoclonal Antibodies Typical Distributors
Table 118. Biosimilar Monoclonal Antibodies Typical Customers

LIST OF FIGURES

Figure 1. Biosimilar Monoclonal Antibodies Picture
Figure 2. Global Biosimilar Monoclonal Antibodies Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Biosimilar Monoclonal Antibodies Consumption Value Market Share by Type in 2023
Figure 4. Infliximab Examples
Figure 5. Rituximab Examples
Figure 6. Trastuzumab Examples
Figure 7. Adalimumab Examples
Figure 8. Other Examples
Figure 9. Global Biosimilar Monoclonal Antibodies Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 10. Global Biosimilar Monoclonal Antibodies Consumption Value Market Share by Application in 2023
Figure 11. Oncology Examples
Figure 12. Autoimmune Disease Examples
Figure 13. Other Examples
Figure 14. Global Biosimilar Monoclonal Antibodies Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 15. Global Biosimilar Monoclonal Antibodies Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 16. Global Biosimilar Monoclonal Antibodies Sales Quantity (2019-2030) & (K Units)
Figure 17. Global Biosimilar Monoclonal Antibodies Average Price (2019-2030) & (USD/Unit)
Figure 18. Global Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Manufacturer in 2023
Figure 19. Global Biosimilar Monoclonal Antibodies Consumption Value Market Share by Manufacturer in 2023
Figure 20. Producer Shipments of Biosimilar Monoclonal Antibodies by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 21. Top 3 Biosimilar Monoclonal Antibodies Manufacturer (Consumption Value) Market Share in 2023
Figure 22. Top 6 Biosimilar Monoclonal Antibodies Manufacturer (Consumption Value) Market Share in 2023
Figure 23. Global Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Region (2019-2030)
Figure 24. Global Biosimilar Monoclonal Antibodies Consumption Value Market Share by Region (2019-2030)
Figure 25. North America Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 26. Europe Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 27. Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 28. South America Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 29. Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value (2019-2030) & (USD Million)
Figure 30. Global Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Type (2019-2030)
Figure 31. Global Biosimilar Monoclonal Antibodies Consumption Value Market Share by Type (2019-2030)
Figure 32. Global Biosimilar Monoclonal Antibodies Average Price by Type (2019-2030) & (USD/Unit)
Figure 33. Global Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 34. Global Biosimilar Monoclonal Antibodies Consumption Value Market Share by Application (2019-2030)
Figure 35. Global Biosimilar Monoclonal Antibodies Average Price by Application (2019-2030) & (USD/Unit)
Figure 36. North America Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Type (2019-2030)
Figure 37. North America Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 38. North America Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Country (2019-2030)
Figure 39. North America Biosimilar Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
Figure 40. United States Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 41. Canada Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 42. Mexico Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 43. Europe Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Type (2019-2030)
Figure 44. Europe Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 45. Europe Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Country (2019-2030)
Figure 46. Europe Biosimilar Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
Figure 47. Germany Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. France Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. United Kingdom Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. Russia Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 51. Italy Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 52. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Type (2019-2030)
Figure 53. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 54. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Region (2019-2030)
Figure 55. Asia-Pacific Biosimilar Monoclonal Antibodies Consumption Value Market Share by Region (2019-2030)
Figure 56. China Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. Japan Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. Korea Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. India Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. Southeast Asia Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. Australia Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 62. South America Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Type (2019-2030)
Figure 63. South America Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 64. South America Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Country (2019-2030)
Figure 65. South America Biosimilar Monoclonal Antibodies Consumption Value Market Share by Country (2019-2030)
Figure 66. Brazil Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 67. Argentina Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 68. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Type (2019-2030)
Figure 69. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Application (2019-2030)
Figure 70. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Quantity Market Share by Region (2019-2030)
Figure 71. Middle East & Africa Biosimilar Monoclonal Antibodies Consumption Value Market Share by Region (2019-2030)
Figure 72. Turkey Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. Egypt Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. Saudi Arabia Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 75. South Africa Biosimilar Monoclonal Antibodies Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 76. Biosimilar Monoclonal Antibodies Market Drivers
Figure 77. Biosimilar Monoclonal Antibodies Market Restraints
Figure 78. Biosimilar Monoclonal Antibodies Market Trends
Figure 79. Porters Five Forces Analysis
Figure 80. Manufacturing Cost Structure Analysis of Biosimilar Monoclonal Antibodies in 2023
Figure 81. Manufacturing Process Analysis of Biosimilar Monoclonal Antibodies
Figure 82. Biosimilar Monoclonal Antibodies Industrial Chain
Figure 83. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 84. Direct Channel Pros & Cons
Figure 85. Indirect Channel Pros & Cons
Figure 86. Methodology
Figure 87. Research Process and Data Source


More Publications